LACTOLOGY FOUNDATION

Aloglutamol (A02AB06) and Breastfeeding

Aloglutamol is an antacid belonging to the group of aluminium compounds used for the treatment of hyperacidity and related upper gastrointestinal disorders. It is a salt of aluminium, gluconic acid and tromethamine, typically administered orally in doses of 0.5–1 g as needed for symptomatic relief.

From a lactation perspective, aloglutamol is prescribed infrequently and there are no clinical studies directly evaluating its transfer into human milk or its effects on the breastfed infant. In line with general experience that most medicines pass into breast milk in very small amounts that are rarely harmful, antacids such as aluminium compounds are usually considered compatible with breastfeeding when used at standard doses and for short periods. However, due to aluminium content and the absence of specific lactation data, a careful individual risk–benefit assessment remains essential.

Pharmacology relevant to lactation

Aloglutamol acts locally in the stomach by neutralising hydrochloric acid, without causing an abrupt rise in gastric pH, which may reduce rebound hypersecretion. After administration, tromethamine reacts with hydrochloric acid to form its hydrochloride salt, while aluminium gluconate dihydroxide binds gastric acid and forms aluminium chloride and free gluconic acid. Systemic exposure of the mother to intact aloglutamol is therefore expected to be low, which theoretically limits its passage into breast milk.

Nevertheless, aluminium can accumulate in the body, especially in patients with renal impairment, and chronic exposure has been associated with neurotoxicity and effects on bone in vulnerable populations. For a breastfed infant, the theoretical concern relates to repeated maternal dosing over longer periods, which could potentially increase infant aluminium exposure, although quantitative data for aloglutamol during breastfeeding are lacking. In clinical practice, occasional short‑term use at recommended doses is unlikely to pose significant risk to a healthy term infant, while prolonged or high‑dose use should be avoided or closely supervised.

Potential effects on the breastfed infant

Because no specific measurements of aloglutamol or its aluminium component in human milk have been published, potential effects on the breastfed infant remain theoretical and must be extrapolated from pharmacology and experience with other antacids. When the mother uses usual therapeutic doses intermittently, clinically significant gastrointestinal or systemic effects in the infant are not expected. In this context, monitoring of the baby is still advisable, with attention to symptoms such as unusual constipation, vomiting, poor feeding or inadequate weight gain.

In cases of preterm infants, neonates with low birth weight, or infants with renal dysfunction, extra caution is warranted due to their reduced capacity to handle aluminium load. If the mother requires long‑term antacid therapy, non‑aluminium alternatives with better established lactation safety profiles may be preferable when clinically appropriate. Any suspicion of adverse effects in the breastfed infant should prompt medical evaluation and reassessment of the maternal therapy.

Clinical recommendations for breastfeeding mothers

For healthy breastfeeding mothers with episodic symptoms of hyperacidity, short‑term use of aloglutamol at the lowest effective dose can be considered, provided that the prescriber is informed about the lactation status. Mothers should avoid exceeding the recommended dosage and duration on the product label, and they should refrain from self‑medicating for prolonged periods without professional advice. When feasible, non‑pharmacological measures for dyspepsia, such as dietary adjustments and spacing of meals, should be implemented alongside or prior to pharmacotherapy.

If a breastfeeding woman requires chronic treatment for acid‑related disorders, clinicians should evaluate alternative agents with more robust breastfeeding safety data and tailor therapy to the mother’s comorbidities and the infant’s clinical status. Shared decision‑making is important, balancing maternal symptom control and quality of life with the theoretical risks of aluminium exposure in the nursing infant. In all cases, regular follow‑up of both mother and child supports early detection of any potential problems.

Toxico‑lactological assessment

From a toxico‑lactological standpoint, the main issue with aloglutamol in breastfeeding is not acute toxicity but possible cumulative aluminium exposure in sensitive infants under conditions of prolonged maternal therapy. Current evidence from general breastfeeding pharmacotherapy suggests that most digestive medicines, when used appropriately, are compatible with breastfeeding, yet the lack of specific data for aloglutamol demands a cautious and individualised approach. Risk mitigation includes limiting treatment duration, using the minimal effective dose, avoiding use in mothers of very premature or renally impaired infants, and considering alternatives with well‑documented lactation safety where long‑term therapy is required.